Puma Biotechnology, Inc. (NASDAQ:PBYI)
Industry: Healthcare

OFF LIST - 1019 consecutive market days: OFF LIST as of 05/17/2012 Through 11/14/2016

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Current Quote*
Last: $10.110
Change: -0.880
Book: $44.496
Volume: 371,112

As Of: 05/29 12:46 ET
*Quotes delayed by 20min.

Graphs for PBYI


3 Month Graph


6 Month Graph


1 Year Graph